Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3.3-K27M Neoantigen Vaccine in DIPG
NCT04749641Phase 1Completed
- Start
- Mar 2021
- Primary completion
- Oct 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of histone H3.3-K27M neoantigen vaccine in diffuse intrinsic pontine glioma (DIPG) (2 arms). Primary endpoints: Safety of histone H3.3-K27M neoantigen vaccine and Rate of the patients who survive for more than one year after surgery/biopsy at 1 year. Started Mar 2021; status: completed.
02
Drugs
histone H3.3-K27M neoantigen vaccine
03
Conditions
diffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT04749641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04749641.